Investigation on the effect of nanoparticle size on the blood–brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice

References

• Alyautdin R, Khalin I, Nafeeza MI, et al. Nanoscale drug delivery systems and the blood–brain barrier. Int J Nanomedicine. 2014;9:795–811.
   PubMed Web of Science ®Google Scholar
• Eyal S, Hsiao P, Unadkat JD. Drug interactions at the blood–brain barrier: fact or fantasy? Pharmacol Ther. 2009;123:80–104.
   PubMed Web of Science ®Google Scholar
• Barar J, Rafi MA, Pourseif MM, et al. Blood–brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6:225–248.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int. 2015;2015:320941.
   PubMed Web of Science ®Google Scholar
• Posadas I, Monteagudo S, Cena V. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis. Nanomedicine (Lond). 2016;11:833–849.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–515.
   PubMed Web of Science ®Google Scholar
• Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood–brain barrier in anaesthetized rats: a developmental study. J Physiol. 1990;429:47–62.
   PubMed Web of Science ®Google Scholar
• Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6:268–286.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Sane R, Oberoi R, et al. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med. 2011;13:e17.
   PubMed Web of Science ®Google Scholar
• Wolburg H, Noell S, Fallier-Becker P, et al. The disturbed blood–brain barrier in human glioblastoma. Mol Aspects Med. 2012;33:579–589.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Manchanda P, Vogelbaum MA, et al. Function of the blood–brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos. 2013;41:33–39.
   PubMed Web of Science ®Google Scholar
• Mattix B, Moore T, Uvarov O, et al. Effects of polymeric nanoparticle surface properties on interaction with brain tumor environment. Nano Life.2013;03:3.1343003.
   Google Scholar
• Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29:770–781.
   PubMed Web of Science ®Google Scholar
• Bronger H, Konig J, Kopplow K, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood–tumor barrier. Cancer Res. 2005;65:11419–11428.
   PubMed Web of Science ®Google Scholar
• Gao H, Pang Z, Jiang X. Targeted delivery of nano-therapeutics for major disorders of the central nervous system. Pharm Res. 2013;30:2485–2498.
   PubMed Web of Science ®Google Scholar
• Groothuis DR. The blood–brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro-oncology. 2000;2:45–59.
   PubMed Web of Science ®Google Scholar
• Gu FX, Karnik R, Wang AZ, et al. Targeted nanoparticles for cancer therapy. Nano Today. 2007;2:14–21.
   Web of Science ®Google Scholar
• Fattori S, Becherini F, Cianfriglia M, et al. Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows Arch. 2007;451:81–87.
   PubMed Web of Science ®Google Scholar
• Karim R, Palazzo C, Evrard B, et al. Nanocarriers for the treatment of glioblastoma multiforme: current state-of-the-art. J Control Release. 2016;227:23–37.
   PubMed Web of Science ®Google Scholar
• Mohri M, Nitta H, Yamashita J. Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neurooncol. 2000;49:105–115.
   PubMed Web of Science ®Google Scholar
• Roberts WG, Delaat J, Nagane M, et al. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol. 1998;153:1239–1248.
   PubMed Web of Science ®Google Scholar
• Sarin H, Kanevsky AS, Wu H, et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med. 2009;7:51.
   PubMed Web of Science ®Google Scholar
• Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology. 2008;16:112–125.
   PubMedGoogle Scholar
• Ujfalussy I, Koo E, Sesztak M, et al. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z Rheumatol. 2003;62:155–160.
   PubMed Web of Science ®Google Scholar
• De Jong WH, Hagens WI, Krystek P, et al. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 2008;29:1912–1919.
   PubMed Web of Science ®Google Scholar
• Pissuwan D, Cortie CH, Valenzuela SM, et al. Functionalised gold nanoparticles for controlling pathogenic bacteria. Trends Biotechnol. 2010;28:207–213.
   PubMed Web of Science ®Google Scholar
• Pissuwan D, Niidome T, Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release. 2011;149:65–71.
   PubMed Web of Science ®Google Scholar
• Libutti SK, Paciotti GF, Byrnes AA, et al. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res. 2010;16:6139–6149.
   PubMed Web of Science ®Google Scholar
• Chen H, Dorrigan A, Saad S, et al. In vivo study of spherical gold nanoparticles: inflammatory effects and distribution in mice. PLoS One. 2013;8:e58208.
   PubMed Web of Science ®Google Scholar
• Kim W, Kang BR, Kim HY, et al. Real-time imaging of glioblastoma using bioluminescence in a U-87 MG xenograft model mouse. J Korean Soc Appl Biol Chem. 2015;58:243–248.
   Google Scholar
• Hernandez R, Sun H, England CG, et al. ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors. Mol Pharm. 2016;13:2563–2570.
   PubMedGoogle Scholar
• Connor EE, Mwamuka J, Gole A, et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1:325–327.
   PubMed Web of Science ®Google Scholar
• Coulter JA, Jain S, Butterworth KT, et al. Cell type-dependent uptake, localization, and cytotoxicity of 1.9 nm gold nanoparticles. Int J Nanomedicine. 2012;7:2673–2685.
   PubMed Web of Science ®Google Scholar
• Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev. 2011;40:1647–1671.
   PubMed Web of Science ®Google Scholar
• Lasagna-Reeves C, Gonzalez-Romero D, Barria MA, et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun. 2010;393:649–655.
   PubMed Web of Science ®Google Scholar
• Shukla R, Bansal V, Chaudhary M, et al. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir. 2005;21:10644–10654.
   PubMed Web of Science ®Google Scholar
• Jain S, Hirst DG, O'Sullivan JM. Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012;85:101–113.
   PubMed Web of Science ®Google Scholar
• Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul. 2007; 1:37–51.
   PubMedGoogle Scholar
• Kah JC, Kho KW, Lee CG, et al. Early diagnosis of oral cancer based on the surface plasmon resonance of gold nanoparticles. Int J Nanomedicine. 2007;2:785–798.
   PubMed Web of Science ®Google Scholar
• Cai W, Gao T, Hong H, et al. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl. 2008;1:17–32.
   PubMedGoogle Scholar
• Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49:N309–N315.
   PubMed Web of Science ®Google Scholar
• Sriraman SK, Aryasomayajula B, Torchilin VP. Barriers to drug delivery in solid tumors. Tissue Barriers. 2014;2:e29528.
   PubMedGoogle Scholar
• Dorsey JF, Sun L, Joh DY, et al. Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization. Transl Cancer Res. 2013;2:280–291.
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M, Friden M, Syvanen S, et al. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25:1737–1750.
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M. In Vivo Approaches to Assessing the Blood–Brain Barrier. In: Fricker G, Ott M, Mahringer A, editors. The blood brain barrier (BBB). Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 21–48.
   Google Scholar
• Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol. 1984;247:H484–H493.
   PubMed Web of Science ®Google Scholar
• Smith QR, Allen DD. In situ brain perfusion technique. Methods Mol Med. 2003;89:209–218.
   PubMedGoogle Scholar
• Zhao R, Kalvass JC, Pollack GM. Assessment of blood–brain barrier permeability using the in situ mouse brain perfusion technique. Pharm Res. 2009;26:1657–1664.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood–brain barrier delivery. Drug Discov Today. 2007;12:54–61.
   PubMed Web of Science ®Google Scholar